: Sanofi shares skid as French drugmaker outlines higher R&D expenses, taxes

Shares of French drugmaker Sanofi fell as much as 16% on Friday after after hiking its research-and-development expense guidance as well as its expectations for taxes.

Previous post Bond Report: Bond yields edge higher ahead of PCE inflation data
Next post Movers & Shakers: Shares of Amazon, Intel climb after earnings beats, as NatWest and Sanofi tumble on warnings, and other stocks on the move